Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology Academic Article uri icon

Overview

MeSH Major

  • Antigens, Tumor-Associated, Carbohydrate
  • Biomarkers, Tumor
  • Neoplasms
  • Positron-Emission Tomography
  • Radioisotopes
  • Zirconium

abstract

  • In this report, a general strategy to supplement some of the shortcomings of otherwise highly useful circulating biomarkers with immunoPET is described. To expedite the clinical validation of this model, a human monoclonal antibody to CA19.9 (a highly visible but partially flawed serum biomarker for several cancers) was radiolabeled and evaluated, and the compelling preclinical evidence suggests that the radiotracer may enhance the fidelity of diagnosis and staging of pancreatic ductal adenocarcinoma, a notoriously occult cancer.

publication date

  • November 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4274751

Digital Object Identifier (DOI)

  • 10.2967/jnumed.113.119867

PubMed ID

  • 24029655

Additional Document Info

start page

  • 1876

end page

  • 82

volume

  • 54

number

  • 11